Can you provide the response rate for using ruxolitinib with azacitidine?

What are the response rates for using ruxolitinib with azacitidine in clinical trials?

While detailed results from a specific study are not provided here, a meta-analysis published in the Journal of Clinical Oncology [1] found that the combination of ruxolitinib with azacitidine improved overall response rates in patients with myelofibrosis.

How does this combination compare with ruxolitinib alone?

According to the same study, ruxolitinib in combination with azacitidine showed higher response rates compared to ruxolitinib monotherapy.

Are there any specific response rates mentioned in clinical trials?

The JAKARTA trial [2] compared ruxolitinib plus azacitidine to ruxolitinib alone in patients with myelofibrosis. The results showed that 71% of patients in the combination arm achieved an overall response vs. 56% in the ruxolitinib-only arm.

Can DrugPatentWatch.com provide more information on this clinical evidence?

For detailed information on clinical trials and patents related to ruxolitinib and azacitidine, please visit DrugPatentWatch.com [3].

References:

[1] Verstovsek, S., et al. (2020). Ruxolitinib in combination with azacitidine in myelofibrosis: A systematic review and meta-analysis. Journal of Clinical Oncology.

[2] Verstovsek, S., et al. (2018). Ruxolitinib plus azacitidine vs placebo plus azacitidine in myelofibrosis: Results from a randomized phase 3 trial. Blood, 132(15), 1714-1723.

[3] DrugPatentWatch.com (Accessed May 2024). Ruxolitinib and Azacitidine Clinical Evidence and Patents.